Methods of inhibiting α v β 3 -mediated binding...

Details Methods of inhibiting α v β 3 -mediated binding... Methods of inhibiting α v β 3 -mediated binding...

2008-05-13

2008-05-13

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S153100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C536S023100, C536S023500, C536S023530

Reexamination Certificate

active

07371382

ABSTRACT:
The invention provides enhanced LM609 grafted antibodies exhibiting selective binding affinity to αVβ3, or a functional fragment thereof. The invention also provides nucleic acid molecules encoding the enhanced LM609 grafted antibodies. Additionally provided are methods of inhibiting a function of αVβ3by contacting αVβ3with an enhanced LM609 grafted antibody.

REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5264563 (1993-11-01), Huse
patent: 5523388 (1996-06-01), Huse
patent: 5578704 (1996-11-01), Kim et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6531580 (2003-03-01), Huse et al.
patent: 6590079 (2003-07-01), Huse et al.
patent: 0 451 216 (1991-10-01), None
patent: 0 682 040 (1995-11-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 96/40250 (1996-12-01), None
patent: WO 98/33919 (1998-08-01), None
Biotechnology Newswatch, pp. 11-12, Jan. 16, 1995.
Biotechnology Newswatch, pp. 11, Feb. 6, 1995.
Carmeliet, Peter, “Integrin indecision”Nature Medicine8:14-16 (2002).
Cheresh and Stupack, “Integrin-mediated death: An explanation of the integrin-knockout phenotype?”Nature Medicine8:193-194 (2002).
Posey, et al., A Pilot Trial of Vitzin, A Humanized Anti-Vitronection Receptor (anti αvβ3) Antibody in Patients with Metastatic Cancer.
Reynolds et al., “Enhanced pathological angiogenesis in mice lacking β3integrin or β3and β5integrins,”Nature Medicine8:27-34 (2002).
Studnicka et al., “Human engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues,” Protein Engineering 7:805-814 (1994).
Stupack and Cheresh, “Get a ligand, get a life: integrins, signaling and cell survival,”J. Cell Science115:3729-3738 (2002).
Adams et al., “Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies,”Cancer Res., 58:485-490 (1998).
Alfthan,Biosensors and Bioelectronics, “Surface plasmon resonance biosensors as a tool in antibody engineering,” 13:653-663 (1998).
Biedler, C., “Mammalian expression and characterization of a dimeric single chain antibody specific for integrin alpha-v-beta-3,”Immunotech., 2:297 (1996).
Brooks et al., “Integrin αVα3 Antagonists Promote Turmor Regression by Inducing Apoptosis of Angiogenic Blood Vessels”Cell79:1157-1164 (1994).
Cheresh, D.A., “Human endothelial cells syntehsize and express and Arg-Gly-Asp-directed adhesion receptor involved n attachment to fibrinogen and von Willebrand factor”Proc. Natl. Acad. Sci. USA84:6471-6475.
Cheresh and Spiro, “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor”J. Viol. Chem.262(36) :17703-17711 (1987).
Choi et al., “Inhibition of neointimal hypersplasia by blocking αVβ3 integrin with a small peptide antagonistGpenGRGDSPCA” J. Vascular Surg., 19:125-134 (1994).
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”J. Mol. Biol.196:901-917 (1987).
Chowdhury et al., “Improving antibody affinity by mimicking somatic hypermuation in vitro,”Nature Biotech., 17:568-572 (1999).
Clark, M. (ed.), “Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man,” Nottingham, England: Academic Titles (1993).
Davies et al., “Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding,”Immunotech., 2:169-179 (1996).
Day, E.D.,Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc., New York, NY (1990).
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”Science249:404-406, (1990).
Dueñas et al., “Selection of Phage Displayed Antibodies Based on Kinetic Constants,”Molec. Immunol., 33(3) :279-285 (1996).
Foote and Milstein, “Kinetic maturation of an immune response”Nature352:530-532 (1991).
Glaser et al., “Antibody Engineering by Condon-Based Mutagenesis in a Filamentous Phage Vector System”J. Immunol.149:3903-3913 (1992).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity, Mimicking Affinity Maturation,”J. Mol. Biol., 226:889-896 (1992).
Huse, W.D., “Combinatorial Antibody Expression Libraries in Filamentous Phage” In: Antibody Engineering: A Practical Guide, C.A.K. Borrebaeck, ed. W.H. Freeman and Co., Publishers, New York, pp. 103-120 (1991).
Huse et al., “Application of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenesis of F (ab) Antibody Fragments”J. Immunol.149:3914-3920 (1992).
Huston et al., “Antigen Recognition and Targeted Delivery by the Single-Chain Fv”Cell Biophysics, 22:189-224 (1993).
Kabat et al., U.S. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” vol. 1 pp. i-xcvi (1991).
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”J. Mol. Biol.262:732-745 (1996).
Moore et al., “Directed evolution ofpara-nitrobenzyl esterase for aqueous-organic solvents”Nature Biotechnology14:458-467 (1996).
Myszka et al., “Kinetic analysis of a protein antigen-antibody interaction limited by mass transportation on an optical biosensor,”Biophys. Chem., 64:127-137 (1997).
Newman et al., ““Primatization” of Recombinant Antibodies for Immunotherapy of Human Diseases: A Macaque/Human Chimeric Antibody Against Human CD4,”Biotechnol., 10:1455-1460 (1992).
Padlan, Eduardo A., “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties”Molecular Immunol.28(4/5) :489-498 (1991).
Plückthun and Skerra, “Expression of functional antibody Fv and Fab fragments inEscherichia coli,” Meth. Enzymol.178:497-515 (1989).
Rader et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries”Proc. Natl. Acad. Sci.95:8910-8915 (Jul. 1998).
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab”J. Biol. Chem.271:22611-22618 (1996).
Sandberg and Terwilliger, “Engineering multiple properties of a protein by combinatorial mutagenesis”Proc. Natl. Acad. Sci.90:8367-8371 (1993).
Schier et al., “Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain fv by Molecular4 Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site,”J. Mol. Biol., 263:551-567 (1996).
Schier et al., “Isolation of High-Affinity Monomeric Human Anti-c-ervB-2 Single-chain Fv Using Affinity-driven Selection,”J. Mol. Biol., 255:28-43 (1996.
Schier and Marks, “Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections,”Hum. Antibod. Hybridomas, 7:97-105 (1996).
Singer et al., “Optimal Humanization of 1B4, an Anti-CD18 Murine Monoclonal Antibody, is Achieved by Correct Choice of Human V-Region Framework Sequences”J. Immunol.150 (7) :2844-2857 (1993).
Thompson et al., “Affinity Maturation of a High-Affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phage Display to Improve Affinity and Broaden Strain Reactivity,”J. Mol. Biol., 256:77-88 (1996).
Wu et al., “Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb,&#x

Affiliated with

Also associated with

Rating

Methods of inhibiting α v β 3 -mediated binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of inhibiting α v β 3 -mediated binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting α v β 3 -mediated binding... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2813263